Anaphylaxis Management in Pediatric Patients

Critical First-Line Treatment Priority

The American Academy of Allergy, Asthma, and Immunology recommends intramuscular epinephrine must be administered immediately at 0.01 mg/kg (maximum 0.3 mg in children) into the anterolateral thigh as the first-line treatment for anaphylaxis, with famotidine and other H2-receptor antagonists being second-line adjunctive therapies only 2, 3
The American College of Allergy, Asthma, and Immunology states that famotidine and other H2-receptor antagonists should never delay or replace epinephrine administration 1, 4

The American Academy of Pediatrics recommends a dose of 1 mg/kg intravenously for acute allergic reactions/anaphylaxis, diluted in 5% dextrose (D5W) to a total volume of 20 mL, and injected slowly over 5 minutes 1
The American College of Allergy, Asthma, and Immunology suggests that ranitidine 1 mg/kg IV can be used similarly if famotidine is unavailable 1

The combination of an H1-antihistamine (diphenhydramine) plus an H2-antagonist (ranitidine or famotidine) is superior to diphenhydramine alone in managing anaphylaxis symptoms, according to the American Academy of Allergy, Asthma, and Immunology 1, 4
The American College of Allergy, Asthma, and Immunology notes that these agents have a much slower onset of action (≥1 hour) compared to epinephrine and do not relieve respiratory symptoms or shock 2

The American Heart Association recommends establishing IV access, providing oxygen, and monitoring vital signs after administering epinephrine 2
The American Academy of Pediatrics suggests administering crystalloid fluid bolus (20-30 mL/kg for severe reactions) after establishing IV access 2

The American College of Allergy, Asthma, and Immunology states that H2-antagonists have a slow onset of action, taking approximately 1 hour to achieve therapeutic effect 2
The American Academy of Allergy, Asthma, and Immunology notes that H2-antagonists are primarily helpful for cutaneous symptoms and potentially preventing prolonged reactions, but are not life-saving 1, 4

The American College of Allergy, Asthma, and Immunology recommends observing patients for a minimum 6 hours in a monitored setting after administering famotidine as adjunctive therapy 2, 3
The American Academy of Allergy, Asthma, and Immunology suggests watching for biphasic reactions, which can occur despite initial treatment 1, 4